Insider Buying: Sensei Biotherapeutics (NASDAQ:FTH) CEO Acquires 2,806 Shares of Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CEO Anand Kiran Parikh acquired 2,806 shares of the firm’s stock in a transaction on Monday, June 22nd. The shares were acquired at an average price of $19.76 per share, with a total value of $55,446.56. Following the completion of the purchase, the chief executive officer owned 764,234 shares of the company’s stock, valued at $15,101,263.84. This trade represents a 0.37% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Sensei Biotherapeutics Trading Up 2.2%

Shares of FTH stock traded up $0.54 during mid-day trading on Wednesday, reaching $24.54. The company’s stock had a trading volume of 102,858 shares, compared to its average volume of 189,941. Sensei Biotherapeutics, Inc. has a 12-month low of $6.32 and a 12-month high of $36.76. The company has a market cap of $32.93 million, a PE ratio of -0.17 and a beta of -0.25.

More Sensei Biotherapeutics News

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: HC Wainwright maintained a bullish stance on Sensei Biotherapeutics and reiterated a $60 target, which may have supported investor sentiment despite the company’s expected losses.
• Neutral Sentiment: The firm updated multiple earnings estimates for 2026-2030, forecasting continued losses in the near and medium term, including EPS estimates of ($0.63) for Q2 2026, ($0.69) for Q3 2026, and ($0.75) for Q4 2026.
• Neutral Sentiment: HC Wainwright also projected losses for later years, including FY2027 EPS of ($3.72), FY2028 EPS of ($3.19), FY2029 EPS of ($3.16), and FY2030 EPS of ($3.07), reflecting a long path to profitability.

Analyst Ratings Changes

A number of research analysts have commented on the company. BTIG Research upgraded Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, June 11th. HC Wainwright started coverage on Sensei Biotherapeutics in a report on Monday. They issued a “buy” rating and a $60.00 price target for the company. Finally, Weiss Ratings initiated coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Sensei Biotherapeutics has a consensus rating of “Moderate Buy” and an average price target of $60.00.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.